Assertio Holdings, Inc.

NASDAQ:ASRT

Drug Manufacturers - Specialty & Generic

Healthcare
$23.50 +0.04%

+$0.01 today

Market cap
$151.86M
Beta
0.53
P/E (TTM)
-4.2
EPS (TTM)
-$5.55
52W Low $8.61High $23.50

Volume 0.27M

Average 0.33M

ASRT Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Assertio Holdings, Inc.NASDAQ: ASRT

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense dips below year-ago levels

Q1 FY2026 income tax expense of $45K fell 81.6% year over year, behind the +42.4% change in trailing-twelve-month income tax expense. Sequentially, it fell 75.1% from the prior quarter.

Context

  • Income tax expense amounted to 0.4% of revenue in FY2025, up 0.3 pp from a year earlier.
  • Income tax expense increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly growth recovers from -81.6% toward the trailing-twelve-month pace of +42.4%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$45K-75.1% QoQ
Last fiscal yearDec 2025
$435K+736.5% YoY
LTMMar 2026
$235K+42.4% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-81.6%——
1 year+736.5%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
435K USD
Year-over-year change
+736.5%
4-year CAGR
-12.1%

Income Tax Expense vs competitors

How ASRT compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of +42.4% is the 5th highest of 7, against a peer median of +71.3%.
  • Income tax expense amounts to 0.2% of revenue for ASRT, versus a peer median of 0.4%.
ASRT Competitors
Income Tax Expense for ASRT and competitors
Company Period LTM YoY 3-year CAGR% of revenue
FBIOFortress Biotech, Inc.LTM Mar 2026$4.34M USD+972.1%—6.6%
LUNGPulmonx CorporationLTM Mar 2026$640K USD+42.5%+21.0%0.7%
VXRTVaxart, Inc.LTM Mar 2026$410K USD+32.3%+92.2%0.2%
XBITXBiotech Inc.LTM Mar 2026$255K USD+1010.7%——
ASRTAssertio Holdings, Inc.LTM Mar 2026$235K USD+42.4%—0.2%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$25K USD+100.1%——
TCRXTScan Therapeutics, Inc.LTM Mar 2026$0 USD——0.0%
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 USD———
NTRBNutriband Inc.LTM Apr 2026$0 USD——0.0%
INCRInterCure Ltd.LTM Jun 2025-₪15.53M ILS-389.2%—6.4%
Peer median (excluding ASRT) —+71.3%+56.6%0.4%

Competitors are the stored peer set for ASRT. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue111.01M156.23M152.07M124.96M118.71M
Cost of Revenue15.83M18.75M27.02M39.23M65.39M
Gross Profit95.18M137.49M125.05M85.73M53.33M
Gross Margin85.7%88.0%82.2%68.6%44.9%
Research & Development002.84M3.82M1.69M
Selling, General & Admin56.56M48.1M69.74M76.95M68.86M
Operating Expenses85.76M98.08M368.59M110.21M70.55M
Depreciation & Amortization29.11M33.4M28.23M25.83M30.01M
EBITDA38.78M90.17M53.17M5.15M3.14M
EBITDA Margin34.9%57.7%35.0%4.1%2.6%
Operating Income9.42M39.41M(243.54M)(24.48M)(17.22M)
Operating Margin8.5%25.2%-160.1%-19.6%-14.5%
Interest Income0003.22M2.67M
Interest Expense10.22M7.96M3.38M3.04M3.08M
Other Income / Expenses(9.98M)(8.24M)(10.52M)2.95M(12.72M)
Income Before Tax(553K)31.17M(254.05M)(21.53M)(29.94M)
Pre-Tax Margin-0.5%19.9%-167.1%-17.2%-25.2%
Income Tax Expense728K(78.46M)77.89M52K435K
Net Income(1.28M)109.63M(331.94M)(21.58M)(30.38M)
Net Margin-1.2%70.2%-218.3%-17.3%-25.6%
EPS (Basic)(0.45)34.95(70.05)(3.45)(4.74)
EPS (Diluted)(0.45)30.45(70.05)(3.45)(4.74)
Weighted Avg Shares2.88M3.13M4.74M6.35M6.4M
Weighted Avg Shares (Diluted)2.88M3.64M4.74M6.35M6.4M

Assertio Holdings, Inc.

NASDAQ:ASRT

Intrinsic Alpha fair value

Locked

Current Price

$23.50

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.